HomeProductsBioactive CompoundsApoptosisc-RETSelpercatinib
Chemical structure of CAS 2152628-33-4

Selpercatinib

CAS No.2152628-33-4
MDL No.MFCD31814089
MFC29H31N7O3
MW525.60
InChI KeyXIIOFHFUYBLOLW-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.2152628-33-4
Product NameSelpercatinib

Biological Targets

RET·CCDC6·KIF5B

Associated Conditions

follicular thyroid carcinoma·non-small cell lung carcinoma·cancer·liver disease·thyroid cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with Gene Mutations or Fusions.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 27, Issue 8 • 2021
PMID: 33239432DOI: 10.1158/1078-0432.CCR-20-3558

Selective RET kinase inhibition for patients with RET-altered cancers.

Annals of oncology : official journal of the European Society for Medical Oncology • Vol. 29, Issue 8 • 2018
PMID: 29912274PMC: PMC6096733DOI: 10.1093/annonc/mdy137

Spin labels as probes for tetraphenylboron ion interaction with liposomes.

Canadian journal of biochemistry • Vol. 54, Issue 4 • 1976
PMID: 5182DOI: 10.1139/o76-048

Documentation

Similar Products